‘Disease Doesn’t Respect Silos’: Sharpless Sets Flexibility As Priority
Acting US FDA Commissioner Ned Sharpless described his vision for an efficient, adaptable agency on 2 May at the Food & Drug Law Institute’s annual conference in Washington, DC.
You may also be interested in...
Among Stephen Hahn’s priorities and long-term ambitions for his time at the US agency are retaining and recruiting the best possible professional staff, and collection and use of data, regulatory consultants and attorneys say.
The US Centers for Medicare and Medicaid Services will allow device manufacturers to submit requests for HCPCS codes for emerging technology on a semi-annual basis, and drug-makers will be allowed to submit quarterly, CMS chief Seema Verma told an MDMA audience at the industry advocacy group's annual meeting on 2 May.
In a farewell talk at the Brookings Institution, outgoing US FDA Commissioner Scott Gottlieb said a top unfinished business that he hopes gets done after his April departure is legislation to regulate laboratory developed tests. While FDA had been looking to issue guidance on LDTs, he argues there isn’t sufficient legal authority for the agency to regulate the sector.